Authors

Latest:

Dr. Agarwala on Entinostat for Patients with Melanoma Who Progress on PD-1/PD-L1 Blockade

Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of entinostat for patients with melanoma who progress on a PD-1/PD-L1 blocking antibody.

Sanjiv S. Agarwala, MD, Temple University School of Medicine

Santhosh Upadhyaya, MD

Latest:

Dr. Upadhyaya Discusses Drug Development for Pediatric Patients With Brain Tumors

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses drug development for pediatric patients with brain tumors.

Santiago Sherwell-Cabello, MD

Latest:

Dr. Sherwell-Cabello on Prognostic Impact of TILs and SILs in TNBC

Santiago Sherwell-Cabello, MD, breast surgical oncology, Instituto de Enfermedades de la Mama, discusses the prognostic impact of tumor-infiltrating lymphocytes and stromal-infiltrating lymphocytes in patients with triple-negative breast cancer (TNBC).

Sara A. Hurvitz, MD

Latest:

HER2CLIMB-02: Primary Analysis of a Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer

Sara A. Hurvitz, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.

Sara A. Hurvitz, MD, David Geffen School of Medicine

Latest:

Treatment Advances in HR+ Breast Cancer

A panel of experts who treat breast cancer close out a discussion on the use of newer therapies, including CDK4/6 inhibitors, based on outcomes demonstrated by recent clinical trials.

Sara A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center

Latest:

Future Directions in HER2-Positive Metastatic Breast Cancer

Sara A. Hurvitz, MD, reviews therapy options for patients with HER2-positive metastatic breast cancer and comments on emerging therapeutic strategies.

Sara Hurvitz, MD

Latest:

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.

Sara Hurvitz, MD, UCLA

Latest:

Coming Soon: THE TALK: Breast Cancer, A Review of Data from the SABCS 2021 Virtual Meeting

Sara Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center

Sara Karlovitch

Latest:

Magrolimab Plus Various Anti-Leukemia Therapies Being Studied for Efficacy in AML

Magrolimab plus combinations of various antileukemia therapies are being investigated for their efficacy in first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia.

Sara L. Douglas, PhD, RN

Latest:

The Benefits for Nurses of Using Psychosocial Cancer Registry Data

Registries, large databases of patient information collected in a systematic, standardized fashion, most often focus on biologic measures, such as pathology, radiology, and laboratory results, to track incidence and prevalence of disease as well as causative factors.

Sara M. Tinsley, MS, PhD, ARNP, AOCN

Latest:

Sara Tinsley Discusses Quality of Life in Patients with High-Risk MDS

Sara M. Tinsley, MS, PhD, ARNP, AOCN, nurse practitioner, malignant hematology, Moffitt Cancer Center, discusses a study that examined quality of life in patients with high-risk myelodysplastic syndromes (MDS).

Sara M. Tolaney, MD, MPH

Sara M Tolaney, MD is

Latest:

Dr Tolaney on Implications of Data for Sacituzumab Govitecan in First-line Advanced TNBC

Sara Tolaney, MD, MPH, discusses the clinical implications of sacituzumab govitecan in the first-line treatment of advanced triple-negative breast cancer.

Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

Latest:

Treatment Advances in HR+ Breast Cancer

A panel of experts who treat breast cancer close out a discussion on the use of newer therapies, including CDK4/6 inhibitors, based on outcomes demonstrated by recent clinical trials.

Sara McLaughlin, MD

Latest:

Dr. McLaughlin on Lymphedema in Breast Cancer

Sara McLaughlin, MD, professor of Surgery, Mayo Clinic, discusses the frequency that lymphedema appears in patients with breast cancer and addresses the complications in identifying this after her presentation at the Lynn Sage Breast Cancer Symposium.

Sara Thier, PhD, MPH

Latest:

New Paradigm Emerging in Multiple Myeloma Therapy

The emerging treatment landscape for patients with high-risk multiple myeloma is burgeoning with new classes of drugs, novel agents, and fresh combination strategies that offer many promising and exciting options for future therapeutic approaches.

Sara Tolaney, MD, MPH, Dana-Farber Harvard Cancer Center

Latest:

Review of Data from the ASCO 2020 Virtual Meeting

Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center

Latest:

Triple-Negative Breast Cancer: Expert Perspectives On Recent Advances

Sarah Alwardt, PhD

Latest:

Real-World Evidence Should Be Part of Clinical Trials in Oncology

As cancer treatment shifts from broad chemotherapy to highly personalized therapies, drug development in oncology is also evolving.